186 related articles for article (PubMed ID: 30379093)
1. Early solid tumor diagnosis through next-generation sequencing of cell-free DNA.
Ziogas DE; Kyrochristos ID; Lykoudis EG; Roukos DH
Biomark Med; 2018 Nov; 12(11):1197-1201. PubMed ID: 30379093
[No Abstract] [Full Text] [Related]
2. Computational Analysis of DNA and RNA Sequencing Data Obtained from Liquid Biopsies.
Marass F; Castro-Giner F; Szczerba BM; Jahn K; Kuipers J; Aceto N; Beerenwinkel N
Recent Results Cancer Res; 2020; 215():347-368. PubMed ID: 31605238
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing in liquid biopsy: cancer screening and early detection.
Chen M; Zhao H
Hum Genomics; 2019 Aug; 13(1):34. PubMed ID: 31370908
[TBL] [Abstract][Full Text] [Related]
4. Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing.
Hellwig S; Nix DA; Gligorich KM; O'Shea JM; Thomas A; Fuertes CL; Bhetariya PJ; Marth GT; Bronner MP; Underhill HR
PLoS One; 2018; 13(7):e0197333. PubMed ID: 30044795
[TBL] [Abstract][Full Text] [Related]
5. Early detection and monitoring of cancer in liquid biopsy: advances and challenges.
Xue VW; Wong CSC; Cho WCS
Expert Rev Mol Diagn; 2019 Apr; 19(4):273-276. PubMed ID: 30760042
[No Abstract] [Full Text] [Related]
6. Technical considerations for circulating tumor DNA detection in oncology.
Franczak C; Filhine-Tresarrieu P; Gilson P; Merlin JL; Au L; Harlé A
Expert Rev Mol Diagn; 2019 Feb; 19(2):121-135. PubMed ID: 30648442
[TBL] [Abstract][Full Text] [Related]
7. Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies.
Abbou SD; Shulman DS; DuBois SG; Crompton BD
Pediatr Blood Cancer; 2019 May; 66(5):e27595. PubMed ID: 30614191
[TBL] [Abstract][Full Text] [Related]
8. Clinical testing should be individualized, not based on populations.
Walt DR
J Clin Invest; 2019 Sep; 129(9):3472-3473. PubMed ID: 31478913
[No Abstract] [Full Text] [Related]
9. A high-throughput protocol for isolating cell-free circulating tumor DNA from peripheral blood.
Pandoh PK; Corbett RD; McDonald H; Alcaide M; Kirk H; Trinh E; Haile S; MacLeod T; Smailus D; Bilobram S; Mungall AJ; Ma Y; Moore RA; Coope R; Zhao Y; Jones SJ; Holt RA; Karsan A; Morin RD; Marra MA
Biotechniques; 2019 Feb; 66(2):85-92. PubMed ID: 30744412
[TBL] [Abstract][Full Text] [Related]
10. Methods for Measuring ctDNA in Lymphomas.
Rossi D; Condoluci A; Spina V; Gaidano G
Methods Mol Biol; 2019; 1881():253-265. PubMed ID: 30350211
[TBL] [Abstract][Full Text] [Related]
11. Bioinformatics Analysis for Cell-Free Tumor DNA Sequencing Data.
Chen S; Liu M; Zhou Y
Methods Mol Biol; 2018; 1754():67-95. PubMed ID: 29536438
[TBL] [Abstract][Full Text] [Related]
12. Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals.
Xia L; Li Z; Zhou B; Tian G; Zeng L; Dai H; Li X; Liu C; Lu S; Xu F; Tu X; Deng F; Xie Y; Huang W; He J
Sci Rep; 2017 Aug; 7(1):7526. PubMed ID: 28790338
[TBL] [Abstract][Full Text] [Related]
13. Correction: Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.
Northcott J; Bartha G; Harris J; Li C; Navarro FCP; Pyke RM; Hong M; Zhang Q; Ma S; Chen TX; Lai J; Udar N; Saldivar JS; Ayash E; Anderson J; Li J; Cui T; Le T; Chow R; Velasco RJ; Mallo C; Santiago R; Bruce RC; Goodman LJ; Chen Y; Norton D; Chen RO; Lyle JM
Oncotarget; 2024 Jun; 15():407. PubMed ID: 38900651
[No Abstract] [Full Text] [Related]
14. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.
Khagi Y; Goodman AM; Daniels GA; Patel SP; Sacco AG; Randall JM; Bazhenova LA; Kurzrock R
Clin Cancer Res; 2017 Oct; 23(19):5729-5736. PubMed ID: 28972084
[No Abstract] [Full Text] [Related]
15. Genetic profiling of cancer with circulating tumor DNA analysis.
Lu L; Bi J; Bao L
J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
[TBL] [Abstract][Full Text] [Related]
16. Single-copy detection of somatic variants from solid and liquid biopsy.
Silva AL; Powalowska PK; Stolarek M; Gray ER; Palmer RN; Herman B; Frayling CA; Balmforth BW
Sci Rep; 2021 Mar; 11(1):6068. PubMed ID: 33727644
[TBL] [Abstract][Full Text] [Related]
17. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
[TBL] [Abstract][Full Text] [Related]
18. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients.
Schwaederle M; Husain H; Fanta PT; Piccioni DE; Kesari S; Schwab RB; Patel SP; Harismendy O; Ikeda M; Parker BA; Kurzrock R
Clin Cancer Res; 2016 Nov; 22(22):5497-5505. PubMed ID: 27185373
[TBL] [Abstract][Full Text] [Related]
19. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
[TBL] [Abstract][Full Text] [Related]
20. Beyond Standard Practice in Liquid Biopsy: Selective Venous Sampling.
Damascelli B; Tichà V; Repetti E; Dorji T
J Vasc Interv Radiol; 2021 May; 32(5):668-671. PubMed ID: 33621662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
